



HR0844

LRB100 20662 MST 36112 r

1

HOUSE RESOLUTION

2

WHEREAS, Eczema is a set of skin conditions that cause red, itchy, and inflamed skin, and has profound medical, psychosocial, and economic effects on patients, families, and their communities; and

3

4

5

6

WHEREAS, The prevalence of eczema in the United States is 10.1 percent; and

7

8

WHEREAS, Eczema affects over 31.6 million children and adults in the United States alone; and

9

10

WHEREAS, Eczema's medical effects include dry, cracked, and scaly skin, incessant itch, chronic pain, and sleep deprivation; and

11

12

13

WHEREAS, 41.5 percent of adult eczema patients report having a co-occurring diagnosis of depression and 47.9 percent report having a co-occurring diagnosis of asthma; and

14

15

16

WHEREAS, Adults and children with eczema also frequently exhibit comorbidities like asthma, allergic rhinitis, food allergies, ADHD, bacterial and viral infections, and hypertension; and

17

18

19

1 WHEREAS, Eczema's disease burden also includes anxiety,
2 stress on social and intimate relationships, increased
3 suicidal ideation, delayed developmental achievement, reduced
4 self-esteem, restrictions on diet and exercise, extensive
5 burdens on caregivers, and challenges with medication
6 adherence; and

7 WHEREAS, Eczema results in missed days of school and work
8 for patients and caregivers, disability, and reduced ability
9 within a patient's chosen profession, including unemployment
10 and underemployment, and other opportunity costs; and

11 WHEREAS, The direct medical costs of the three most common
12 types of eczema exceed \$2.17 billion, and the indirect medical
13 costs exceed \$927 million; and

14 WHEREAS, Two-thirds of eczema patients report experiencing
15 significant access barriers, including high out-of-pocket
16 costs and insurance requirements that delay patients' access to
17 medications; and

18 WHEREAS, There is no cure for eczema, but emerging
19 technologies and medications promise a much brighter future for
20 eczema patients; therefore, be it

21 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE

1 HUNDREDTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that the
2 month of October 2018 is designated as Eczema Awareness Month
3 and residents are encourage to show support for Eczema
4 Awareness.